254 related articles for article (PubMed ID: 23930754)
21. Successes and limitations of targeted cancer therapy in lung cancer.
Suda K; Mitsudomi T
Prog Tumor Res; 2014; 41():62-77. PubMed ID: 24727987
[TBL] [Abstract][Full Text] [Related]
22. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.
Gately K; O'Flaherty J; Cappuzzo F; Pirker R; Kerr K; O'Byrne K
J Clin Pathol; 2012 Jan; 65(1):1-7. PubMed ID: 22039281
[TBL] [Abstract][Full Text] [Related]
23. The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.
Melosky B; Wheatley-Price P; Juergens RA; Sacher A; Leighl NB; Tsao MS; Cheema P; Snow S; Liu G; Card PB; Chu Q
Lung Cancer; 2021 Oct; 160():136-151. PubMed ID: 34353680
[TBL] [Abstract][Full Text] [Related]
24. Gefitinib for non-small-cell lung cancer treatment.
D'Incecco A; Cappuzzo F
Expert Opin Drug Saf; 2011 Nov; 10(6):987-96. PubMed ID: 21905963
[TBL] [Abstract][Full Text] [Related]
25. Personalized targeted therapy in advanced non-small cell lung cancer.
Ma PC
Cleve Clin J Med; 2012 May; 79 Electronic Suppl 1():eS56-60. PubMed ID: 22614968
[TBL] [Abstract][Full Text] [Related]
26. Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.
Rebuzzi SE; Zullo L; Rossi G; Grassi M; Murianni V; Tagliamento M; Prelaj A; Coco S; Longo L; Dal Bello MG; Alama A; Dellepiane C; Bennicelli E; Malapelle U; Genova C
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807876
[TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
28. Emerging drugs for squamous cell lung cancer.
Cheng H; Shcherba M; Kandavelou K; Liang Y; Liu H; Perez-Soler R
Expert Opin Emerg Drugs; 2015 Mar; 20(1):149-60. PubMed ID: 25557559
[TBL] [Abstract][Full Text] [Related]
29. Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients.
Santarpia M; De Pas TM; Altavilla G; Spaggiari L; Rosell R
Future Oncol; 2013 Mar; 9(3):327-45. PubMed ID: 23469969
[TBL] [Abstract][Full Text] [Related]
30. New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1).
Russo A; Lopes AR; McCusker MG; Garrigues SG; Ricciardi GR; Arensmeyer KE; Scilla KA; Mehra R; Rolfo C
Curr Oncol Rep; 2020 Apr; 22(5):48. PubMed ID: 32296961
[TBL] [Abstract][Full Text] [Related]
31. Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.
Riess JW; Wakelee HA
Clin Adv Hematol Oncol; 2012 Apr; 10(4):226-34. PubMed ID: 22706483
[TBL] [Abstract][Full Text] [Related]
32. Inhibitors of the anaplastic lymphoma kinase.
Mologni L
Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
[TBL] [Abstract][Full Text] [Related]
33. Molecular targets in the treatment of non-small-cell lung cancer: is there hope on the horizon?
Carter CA; Nations JA; Lazarus A
Postgrad Med; 2014 Nov; 126(7):139-48. PubMed ID: 25387222
[TBL] [Abstract][Full Text] [Related]
34. Drug resistance to targeted therapeutic strategies in non-small cell lung cancer.
Liu WJ; Du Y; Wen R; Yang M; Xu J
Pharmacol Ther; 2020 Feb; 206():107438. PubMed ID: 31715289
[TBL] [Abstract][Full Text] [Related]
35. Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.
Kondo M; Yokoyama T; Fukui T; Yoshioka H; Yokoi K; Nagasaka T; Imaizumi K; Kume H; Hasegawa Y; Shimokata K; Sekido Y
Lung Cancer; 2005 Dec; 50(3):385-91. PubMed ID: 16140420
[TBL] [Abstract][Full Text] [Related]
36. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
Cappuzzo F; Varella-Garcia M; Shigematsu H; Domenichini I; Bartolini S; Ceresoli GL; Rossi E; Ludovini V; Gregorc V; Toschi L; Franklin WA; Crino L; Gazdar AF; Bunn PA; Hirsch FR
J Clin Oncol; 2005 Aug; 23(22):5007-18. PubMed ID: 16051952
[TBL] [Abstract][Full Text] [Related]
37. Targeting HER2 in the treatment of non-small cell lung cancer.
Mar N; Vredenburgh JJ; Wasser JS
Lung Cancer; 2015 Mar; 87(3):220-5. PubMed ID: 25601485
[TBL] [Abstract][Full Text] [Related]
38. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
39. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors.
Haber DA; Bell DW; Sordella R; Kwak EL; Godin-Heymann N; Sharma SV; Lynch TJ; Settleman J
Cold Spring Harb Symp Quant Biol; 2005; 70():419-26. PubMed ID: 16869779
[TBL] [Abstract][Full Text] [Related]
40. Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.
Berge EM; Doebele RC
Semin Oncol; 2014 Feb; 41(1):110-25. PubMed ID: 24565585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
